I am thrilled to join Sigrid at a pivotal moment for the metabolic health category. With its patented SiPore® technology, Sigrid is uniquely positioned to help reshape and revitalise this space in a more sustainable, science-led way.

I am very pleased to welcome Claus Kjaersgaard as our new CEO. Claus has a strong track record of building and scaling health-focused businesses, combining strategic clarity with deep customer and market insight. His experience across regulated health products, international commercialisation, and partnership-driven growth makes him exceptionally well suited to lead Sigrid into its next phase. I would also like to thank Sana Alajmovic for building the strong scientific and commercial foundation of Sigrid and wish her the very best in her next role.

While our primary focus remains the continued commercialization of Carb Fence and Glucose Stabiliser, this partnership allows us to realize additional value from the SiPore® platform through a capital-efficient, non-dilutive approach. It also demonstrates SiPore®’s potential to support multiple large-scale health applications over time and reflects strong validation of the platform following an extensive two-year scientific, technical, and commercial due diligence process conducted by a multinational partner.

Oral health is a demanding category where safety, efficacy, and daily usability are critical. This collaboration enables rigorous scientific validation of SiPore® in oral health, while leveraging a partner with the capabilities to translate that science into products that can reach consumers globally and at scale.

We’re seeing a fundamental shift in how people approach metabolic health. Blood sugar control and sustainable weight management have become top priorities, and expectations for clinically validated solutions are rising. With one of the most well-validated non-systemic platform technologies in the category, Sigrid is uniquely positioned to meet this demand. This investment allows us to accelerate our U.S. expansion while advancing new verticals powered by our SiPore® technology.

Expanding into the physician channel is the next evolution for SIGRID. Physicians want patented, clinically proven tools that make a measurable difference for patients—and SiPore® is standing out as a solution they trust.

bVital Center — Park City, Utah: At bVital, integrating Glucose Stabiliser into our precision protocols has dramatically improved our patients’ glucose time-in-range — a measurable advance that’s been pivotal in reducing neuroinflammation and supporting the body’s innate healing capacity.

Full Circle Health — Edmond, Oklahoma: “Glucose Stabiliser has transformed our patients' wellness journeys at Full Circle Health, empowering them to manage cravings, stabilize blood sugar, and embrace healthier digestion without invasive methods.”, says Barbie Schrick, founder & Clinical Director, Full Circle Health.

I’m thrilled to present our data at EASD, where leading experts come together to advance diabetes care. This is a unique opportunity to highlight how our science can open new pathways for people at risk of, or already living with, type 2 diabetes. By engaging with physicians, researchers, and partners, we can accelerate access to truly innovative solutions that address one of today’s most urgent health challenges.

“This milestone validates the strength of our scientific innovation and the uniqueness of our technology. With the US being a key market, this patent strengthens our commercial position and ability to delivery novel solutions that address some of the most pressing health challenges of our time.

U.S. real-world study shows CarbFence™ reduces appetite, drives weight loss, and preserves muscle – all while working locally in the gut.

This study was designed to capture real-world use, giving us a clear picture of how people integrate CarbFence™ into daily life. The high compliance rates and consistent early outcomes strengthen the validity of the findings and set the stage for understanding longer-term benefits.

With our science validated, manufacturing secured, and regulatory pathways cleared, we’re ready to scale CarbFence™ globally with a partner - bringing affordable, safe, and sustainable weight management to a market desperate for long-term solutions.

Through her visionary leadership and hard work, Sana has laid the foundation for Sigrid’s next growth phase. The Board is grateful for her contributions and wishes her every success in the next chapter

Leading Sigrid from a research idea to a company with patented technology, clinical evidence, and commercial products has been a fantastic journey. I am extremely proud of the dedicated team driving Sigrid forward

What’s remarkable about this study is how definitively the data confirms our mode of action - meal by meal. Participants experienced a dramatic improvement when switching from placebo to Glucose Stabiliser, remaining in the optimal glucose range for almost 100% of the time. The impact is immediately visible and aligns perfectly with what our users report: a near-instant feeling of balance and control. This is science they can feel and measure

These results demonstrate that we’re not only delivering clinically validated benefits but also engaging effectively in a high-demand market. SIGRID is well-positioned for rapid, profitable scaling.

We’re honored that SHINE has been selected for oral presentation at EASD, one of the most prestigious forums for metabolic health science. This recognition supports the clinical relevance of our gut-targeted approach and highlights its potential to offer a safe, drug-free strategy for managing early-stage metabolic disease.

We are very happy to collaborate with Kronans Apotek, which with its more than 500 pharmacies and strong e-commerce has a unique reach in Sweden. This partnership represents a fantastic opportunity to make Sigrid Stabiliser available to more people looking for safe and sustainable solutions to control their blood sugar. We are convinced that this collaboration will be crucial in making preventive healthcare an integral part of people's everyday lives.

We see a great need for products that not only treat but also prevent health problems. Being able to include Sigrid Stabiliser in our range is an important step in making preventive health more accessible to our customers. We are both proud and happy to have been exclusively selected to offer such an innovative and ground-breaking solution for increased wellbeing.

We are thrilled with the results of our test-launch and the overwhelming consumer reception for Glucose Stabiliser. Nearly all of the consumers surveyed were delighted with its multiple positive health effects. With a robust supply chain in place and growing interest from pharmacies and clinics, we are well-positioned to scale and meet increasing demand. This milestone underscores the strength of our scientifically developed solution and its ability to meet the growing demand for safe and effective, non-invasive metabolic health solutions.

The granting of this patent significantly strengthens Sigrid’s global IP portfolio and highlights the versatility of our SiPore® technology in addressing critical metabolic health challenges. The recognition of our product’s potential by the USPTO further validates our expertise in developing groundbreaking silica-based biomaterials for managing blood glucose and reducing the risks of diabetes and related conditions. This milestone enhances the commercial appeal of SiPore® in one of the most important global markets. It comes as we finalize our SHINE clinical trial in people with elevated blood glucose levels who are living with obesity or excess weight, with results expected in QI 2025.

Our vision with SiPore®21 is to transform blood sugar control by delivering an accessible and effective solution that enables millions of individuals worldwide to take charge of their metabolic health. This new patent further solidifies our competitive edge as we advance discussions with leading global consumer healthcare companies and top-performing regional distributors, who have shown strong interest in partnering with us upon achieving regulatory approvals.

Our goal with SiPore21® is to provide an accessible, non-pharmaceutical solution for blood sugar control, empowering millions of individuals worldwide to manage their metabolic health proactively. The high patient interest and remarkably low dropout rate of 6% in the SHINE trial underscore the strong demand for innovative, patient-friendly treatments in this space. Large-scale diabetes studies show that even a modest reduction in HbA1c could delay type 2 diabetes onset by several years, significantly improving public health and reducing healthcare costs globally.

I am delighted to report that enrollment for SHINE has been completed. We observed excellent patient compliance and a very low dropout rate during our visits to the clinics. Importantly, no dropouts were initiated by the investigators themselves. We are on track to complete the study in October and report initial results by year-end. SiPore21® represents a user-friendly, natural approach to blood sugar control and weight management, establishing a pivotal role in the expansive arsenal required for effective diabetes prevention and enhancing global health outcomes.

In the ongoing search for sustainable treatments for sustainable blood sugar and weight management, we believe SiPore21® answers many questions on safety, efficacy, and sustainability. According to a major sector report by Siftel, SiPore21® was highlighted as one of the most promising over-the-counter weight management products. As we reach this milestone of completing patient enrolment in SHINE, Sigrid is actively engaged in discussions with global industry leaders who have shown strong interest in bringing SiPore21® to market. We are swiftly advancing negotiations to commercialize SiPore21® as a medical device in the EU and as a medical food in the US. The opportunity to partner with us in this groundbreaking venture is time sensitive as we move towards product launch.

Patient-friendly, safe, and without negative effects on lean body mass, SiPore® technology could offer a much-needed non-pharmaceutical alternative to injectable drugs for sustainable blood sugar and weight management. Reuters recently reported that the majority of patients discontinue injectable treatments within two years, primarily due to cost and side effects. SiPore21® could address these concerns and help prevent the common weight regain that follows stopping such treatments.

Having seen the technology, scientific portfolio and safety data, it was clear that the potential oral and systemic health benefits of SiPore® are tangible and could be field changing – perhaps the biggest innovation since fluoride!

Caries and periodontitis are among the most prevalent noncommunicable diseases globally, affecting approximately 3.5 billion people. Any method to improve oral health will have significant impacts on individuals and health economics within society. As a dentist, I see great potential for SiPore®, once it becomes commercially available, to become an important tool for both consumers and professionals in enhancing oral health

We’ve had incredible interest in SiPore® and its potential use in oral health right from the beginning. Both from leading experts and oral health companies. I am proud of our achievements and based on our ongoing discussions with global partners, I believe it is realistic to have the first SiPore®-fortified products on the market by the end of 2025.

The study is making good progress and we are grateful to the clinics for the quality of their work. During our visits to the clinics, we observed excellent patient compliance, accompanied by an exceptionally low dropout rate. Crucially, the safety of the study is underscored by the fact that none of the dropouts were initiated by the investigators themselves.We now look forward to including the remaining patients and to completing the study after the summer. SiPore21® represents a user-friendly, natural approach to blood sugar control and obesity management, establishing a pivotal role in the expansive arsenal required for effective diabetes prevention and enhancing global health outcomes.

As SHINE trial results approach, Sigrid is actively engaged in discussions with numerous global industry leaders, demonstrating strong interest in bringing the SiPore21® product to market. With momentum building, Sigrid is swiftly advancing negotiations to commercialize SiPore21® as a medical device in the EU and as a medical food in the US. The opportunity to partner with us in this groundbreaking venture is time-sensitive, as we move swiftly towards product launch.

The SiPore® technology offers a unique non-pharmaceutical alternative to injectable drugs for sustainable blood sugar management, curbs hunger sensations, and reduces bloating. We are excited about the prospect of SiPore21® being a gentler and safer way of achieving sustainable weight control without negative side effects on lean body mass. For patients who discontinue treatment with injectable drugs, SiPore21® could be a way to safeguard against the common weight regain that follows after stopping such treatments.

With SiPore®’s clinical development for obesity and blood sugar control advancing at a rapid pace and funding secured in our recent over-subscribed round, we are ready to accelerate commercialization. After an extensive search, we have identified Cencora as a partner who understands fully our expectations and will be able to help us fulfil our ambition to introduce one of the most important innovations in obesity and diabetes treatment.

“As a leading provider of clinical and commercialization services, we partner with pharmaceutical and biotech companies to help them accelerate product development and efficiently bring products to global markets. We’re thrilled to support Sigrid Therapeutics’ pre-commercial launch preparations as the company moves toward a potential launch in the United States and Europe.

This is a remarkable leap forward in our company’s initiative to continue to present ourselves throughout the U.S. market and empower those seeking to live healthier and more well-rounded lives. Pure Pharmacy’s emphasis on individualized care that empowers its customers to take control of their health is a direct reflection of our own goals and are thrilled to have partnered with them.

We strive at Pure Pharmacy to deliver the most premium prescription and over-the-counter options and are so excited our pharmacy is the exclusive Miami retailer to provide customers with the Glucose Stabiliser.. The company’s dedication to years of research and innovation with its SiPore® technology is truly the driving force behind our decision.”

The Glucose Stabiliser is representative of Sigrid’s mission of empowering those looking to transform their metabolism for the better in an affordable and approachable manner. After seeing my father transition from having difficulty controlling his blood sugar to developing Type 2 Diabetes, it is a personal undertaking just as much as it is professional, to develop innovative treatments that allow users to continue living their life to the fullest, without having to drastically change their lifestyle.

This funding will propel our efforts in establishing key partnerships and driving SiPore® technology to market. We are thrilled to have the backing of our investors as we move closer to providing effective solutions for obesity and diabetes management.

Sigrid's continued success is evident from the launch of one of the world's largest prediabetes trial, SHINE, to SiPore21®'s medical device classification and the commercial traction in our oral health vertical. These accomplishments show the company is well on track to deliver on its exciting potential.

We're pleased that Sigrid Therapeutics' recent share offering was oversubscribed by an impressive 50%. In today's challenging financial climate, this achievement underscores the company's quality and potential. Amidst concerns about obesity and diabetes, the demand for effective, non-drug therapies is evident. This success mirrors investor confidence and Sigrid's commitment to pioneering drug-free solutions.

In the realm of prediabetes management, there's a significant unmet medical need for accessible and user-friendly tools. SiPore21® has the potential to fill this gap effectively. Its innovative approach aligns with the demand for non-pharmaceutical solutions that empower individuals to take control of their health. SiPore21® addresses this critical need, offering hope in the fight against the growing prediabetes epidemic.

At Sigrid, we are entering an exciting phase of development with the launch of the SHINE clinical trial for SiPore21®. Our innovative technology represents a user-friendly, natural approach to blood sugar control and obesity management, setting it apart from modern-day diabetes and obesity pharmaceuticals. We truly believe SiPore21® is going to make a positive impact on the healthcare landscape by preventing diabetes and improving human health worldwide.

This was a very easy decision, having seen the technology, scientific portfolio and safety data, it was clear that the potential oral and systemic health benefits of SiPore® are tangible and could be field changing. I was particularly drawn by the physical rather than chemical mode of action of the technology, its flexibility and broad functionality, which could significantly impact the oral as well as the gut microbiome in a positive manner. Taken together the arguments for significant health benefits are compelling and there is some exciting science to be done.

Through my own research into diabetes, I knew of the connection between bad metabolic health and bad oral health. We are therefore excited to work with Iain and his team to explore the possibility of using our technology to help lessen the burden of sugars in the mouth and improve both related conditions.

By effectively removing amylase, SiPore® decreases the availability of sugar and restricts the growth of pathogenic bacteria and the formation of dental biofilm and plaque. Therefore, as a dentist myself, I believe SiPore® could be one of the biggest innovations in preventative oral health since fluoride. However, in recent years Professor Chapple and others have already shown the links between poor oral health and other systemic metabolic diseases. Which opens even wider potential applications for SiPore®.

There is a very strong link between bad metabolic health and bad oral health, and this is a reason why we looked into this direction. We are excited by the possibility of our technology to help lessen the burden of sugars in the mouth and improve oral health.

As a dentist, I believe SiPore® could be one of the biggest innovations in preventative oral health since fluoride and a game changer in the oral care industry. By effectively removing amylase, SiPore® decreases the availability of sugar and restricts the growth of pathogenic bacteria and the formation of dental biofilm and plaque. SiPore® is compatible with fluoride, but unlike fluoride it exerts its effect before the tooth has started to demineralize. Already we have attracted a great deal of interest among European dental professionals and KOL’s and IDS gives us now the opportunity to introduce SiPore® to the global oral health community. We are interested in collaborating with established oral care companies that seek to co-develop, commercialize, and bring our intellectual property and technology to market successfully

Along with diabetes and obesity, right from the beginning, we identified the oral health market in particular as a major opportunity. Over 3.5 billion people worldwide suffer from oral caries and periodontal disease and with poor nutrition a growing problem, this number will only increase. SiPore® is a truly innovative technology that can make a real difference.

Although we have seen clinically significant effects of the SiPore® technology in previous clinical trials including a 40% larger HbA1c reduction compared to Metformin in prediabetics*, the overwhelmingly positive, subjective ratings from the users exceeded our expectations.